Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia. However, patients with a potential for cure are at risk of severe acute and late adverse effects of treatment. Furthermore, in 25-30% of patients treatment still fails. The objectives of the DCLSG study ALL 8 were to decrease the toxicity and to increase the effectivity of BFM-oriented treatment. Decrease of toxicity was aimed at by confirmation of the results of the previous DCLSG study ALL-7, showing that the majority (94%) of children with ALL can succesfully be treated with BFM-oriented therapy without cranial irradiation, and by reduction of treatment for standard risk (SRG) patients. To increase the cure rate in medium risk (MRG) patients the efficacy of high doses of intravenous 6-mercaptopurine (HD-6MP) during protocol M and in SRG patients the efficacy of high doses of L-asparaginase (HD-L-ASP) during maintenance treatment was studied in randomized studies. Patient stratification and treatment were identical to protocol ALL-BFM90, with the following differences: no prophylactic cranial irradiation, SRG patients received only phase 1 of protocol I. Four hundred and sixtyseven patients entered the protocol: 170 SRG, 241 MRG and 56 HRG patients. The 5 years event-free survival rate for all patients was 73% (s.e. 2%); for SRG, MRG and HRG patients 85% (s.e. 3%), 73% (s.e. 3%) and 39% (s.e. 7%), respectively. In patients Ͼ1 year of age at diagnosis unfavorable prognostic factors were male sex, Ͼ25% blasts in the bone marrow at day 15 and initial white blood cell count (WBC) Ͼ50 × 10 9 /l. The cumulative risk of CNS relapse rate was 5% (s.e. 1%) at 5 years. These results confirm that the omission of cranial irradiation in BFM-oriented treatment does not jeopardize the overall good treatment results, nor does early reduction of chemotherapy in SRG patients. No benefit was observed from treatment intensification with HD-L-ASP in SRG patients, nor from HD-6MP in MRG patients.
Introduction
To further improve the outcome for children with acute lymphoblastic leukemia (ALL) in The Netherlands, the Dutch Childhood Leukemia Study Group (DCLSG) has co-operated with the Berlin-Frankfurt-Mü nster (BFM) Group since 1987 and has adopted their very effective risk adapted treatment strategy. 1 The outcome of the first BFM-oriented protocol, DCLSG ALL-7, 2 showed that: (1) prophylactic cranial irradiation could safely and effectively be substituted by systemic high-dose methotrexate (HD-MTX) and extended intrathecal chemotherapy for the majority of patients and; (2) that delayed intensification (Protocol II) was essential for successful treatment of standard risk patients (SRG).
The DCLSG protocol ALL-8 was based on protocol ALL-BFM 90. 3 BFM treatment for childhood ALL consists of induction treatment (protocol I), high doses of intravenous methotrexate (MTX) in combination with intrathecal MTX (protocol M), delayed intensification (protocol II) and maintenance treatment (for further details: see Appendix). ALL-8 protocol patients were stratified in the same way as ALL-BFM90 patients into standard risk (SRG), medium risk (MRG) and high risk (HRG) groups.
However, in contrast to ALL-BFM90 no prophylactic cranial irradiation was applied to children without initial involvement of the central nervous system (CNS) and SRG patients received only the first part (phase 1) of protocol I and reduced doses of weekly HD-MTX (2 g/m 2 weekly HD-MTX instead of 5 g/m 2 ) during protocol M. In collaboration with other members of the I-BFM-SG 4 Italian (AIEOP), Dutch and Hungarian SRG patients were randomized to receive or not to receive 20 high doses of intramuscular L-asparaginase (HD-L-ASP) during maintenance treatment (IDH-protocol). 5 MRG patients were eligible for a DCLSG study on the effectiveness of high-dose intravenous (i.v.) 6 mercaptopurine (HD-6MP). After obtained consent they were randomized to receive either conventional doses (25 mg/m 2 /day) of 6-mercaptopurine orally (conv. 6-MP) or high doses of 6-MP (i.v.) (HD-6MP) during protocol M.
Patients and methods

Patients
The DCLSG Protocol ALL-8 was open to children (0 to 18 years of age at diagnosis) with de novo acute lymphoblastic Leukemia leukemia (ALL), diagnosed from October 1991 to December 1996. Nearly all patients in The Netherlands are covered by the DCLSG co-operation. Patients with mature B cell-ALL, based on either cytomorphology (French-American-British (FAB) type L3) or immunophenotyping (surface immunoglobulin M positive), as well as patients treated with corticosteroids and/or cytostatic drugs less than 4 weeks before diagnosis were not eligible. The protocol ALL-8 was approved by the Medical Ethical Committees of the participating institutions.
Informed consent was obtained according to institutional guidelines before treatment and, if pertinent, before the randomization in SRG and MRG patients (see below).
Diagnosis
The diagnosis of ALL was made by cytomorphological and cytochemical examination of blood and bone marrow smears at the local institution, and subsequently reviewed and classified according to FAB criteria by the DCLSG laboratory. For the diagnosis of ALL у25% blasts in the bone marrow was mandatory. 6 A sample of cerebrospinal fluid (CSF), mixed 1:1 with a transport medium, was sent to the DCLSG laboratory at diagnosis and when a relapse was suspected. 7, 8 Central nervous system (CNS) involvement was defined as the presence of у5 cells/mm 3 in the CSF with leukemic blasts (cytomorphology) without major blood contamination (Ͻ20 erythrocytes/mm 3 ), or leukemic infiltration of the brain, assessed by cranial computed tomography. Mediastinal mass was defined as a mass of у1/3 thoracic diameter at the level of the 5th thoracic vertebra. The leukemic cell mass estimate, the BFM risk factor RF, was calculated by the equation: RF = 0.2 × log (number of peripheral blood blasts/mm 3 + 1) + 0.06 × liver cm below costal margin + 0.04 × spleen cm below costal margin. 1, 9 Immunophenotyping was performed by the DCLSG laboratory if cytospin bone marrow smears contained у60% blasts. 10 Immunological markers were judged positive if expressed in у20% of the malignant cells.
A leukemia was classified as precursor B-ALL if the malignant cells were positive for TdT, CD19 and HLA-DR (pro-B ALL), or for TdT, CD10, CD19 and HLA-DR (common ALL), or for TdT, CD10, CD19, HLA-DR and CyIg (pre-B-ALL). A T-ALL was defined by positivity for TdT, CD2, cytoplasmic CD3 (CyCD3) and/or CD7. Acute undifferentiated leukemia (AUL) was defined if common-ALL, pre-B, T cell characteristics and also myeloid markers were negative. Cytogenetic analysis was carried out by members of the Dutch Working Party on Cancer Genetics and Cytogenetics at the various Clinical Genetics Centers in The Netherlands. 11 All findings were peer-reviewed before submission to the database. An abnormal clone was defined as a minimum of two metaphases with the same structural abnormality or same additional chromosome, or three metaphases with the same missing chromosome. Cytogenetic analysis was considered a failure if less than 20 metaphases with an apparently normal karyotype from an unstimulated or unsynchronized culture had been analyzed. Chromosome structural abnormality included all structural abnormalities (not just translocations). A patient was classified as unknown if cytogenetics had failed or the metaphases were of insufficient quality to rule out the possibility of structural variation. Cell ploidy was based on cytogenetic findings. The DNA index was measured by the DCLSG laboratory.
Treatment and treatment stratification
Patients were stratified into three groups; standard risk group (SRG), medium risk group (MRG) and high risk group (HRG), identical to the protocol ALL-BFM-90. The treatment is summarized in Table 1 ; details are given in the Appendix.
SRG patients in continuous complete remission (CCR) after protocol II were randomized to receive (SRG2) or not to receive (SRG1) high doses of Erwinia L-asparaginase (Erwinase) (HD-L-ASP) (25 000 IU), intramuscularly (i.m.), weekly, during the first 20 weeks of maintenance treatment. MRG patients in CCR after protocol I were randomized to receive either conventional oral doses of 6-mercaptopurine (25 mg/m 2 /d), orally for 56 days (conv. 6MP) (MRG1) or 4 weekly high doses of 6-mercaptopurine (1300 mg/m 2 ) by 24 h infusion (HD-6MP) (MRG2) immediately after the 24 h infusion of high doses of methotrexate (HD-MTX) during protocol M.
Allogeneic bone marrow transplantation (BMT) after the first series of three HR blocks was optional for HRG patients with a matched sibling donor (MSD), if they had a poor steroid response in combination with a karyotype t(9;22) or BCR-ABL rearrangement, t(4;11) karyotype or 11q23 abnormality or MLL gene rearrangement, no complete remission at day 33, one or more myeloid markers on Ͼ20% of the leukemic blasts, a RF у1.7, pre T-ALL or T-ALL immunophenotype. The total duration of chemotherapy for all patients was 24 months. Patients with involvement of the central nervous system at diagnosis received extra intrathecal therapy during induction protocol I and, if у1 year of age, cranial irradiation (18 Gy) after protocol II (MRG patients) or before maintenance treatment (HRG patients).
Evaluation criteria
After induction treatment patients were evaluated at day 33 for complete remission (CR), which was defined as less than 5% blasts in the bone marrow and recovery of normal hematopoiesis, absence of peripheral blood blasts and no evidence of disease at any other site. Relapse was defined as у25% blasts cells in the bone marrow and/or blasts cells in the peripheral blood, and/or CNS involvement, and/or leukemic infiltration(s) elsewhere.
The prednisone response was evaluated on day 8 after 7 days of monotherapy with prednisone (60 mg/m 2 , orally, daily) and one intrathecal injection of MTX at day 1 (dosage according to age; see Appendix) by counting the absolute number of blasts in the peripheral blood. A good prednisone response was defined as Ͻ1000 blasts/mm 3 , a poor prednisone as у1000 blasts/mm 3 (1 × 10 3 /l). Results of treatment were also evaluated by bone marrow examination on day 15 of protocol I, before the start of protocols M, II, each series of three HR blocks, and every 12-14 weeks during maintenance treatment. All smears were examined at the DCLSG laboratory. Registration forms with data on dosage, toxicity and results of treatment for each patient were sent to the DCLSG Operations Office after protocols I, M, II, a series of three HR blocks or after allogeneic bone marrow transplantation, and every 3 months during maintenance treatment, up to 5 years after cessation of treatment. 
Statistical methods
For comparison of patient and disease characteristics, the Student's t-test, the Mann-Whitney U and the chi-square test were applied. Event-free survival (EFS) was defined as the time from diagnosis to induction failure, relapse, death in remission, or the occurrence of a second tumor. For patients event-free alive at latest follow-up (censored observations) EFS was calculated till this latest follow-up. Patients who did not achieve remission were included in the analysis and considered as treatment failures with EFS of 0 days. The survival time was calculated from diagnosis to death; the time from diagnosis to latest follow-up evaluation was calculated as survival time for patients alive, the so-called censored observations. All analyses were based on 'intention to treat' on data for all patients who entered the study; no patients have been excluded for whatever reason (treatment refusal, toxicity, etc). Survival curves and standard errors were calculated according to the Kaplan-Meier method. Within each of the three risk groups the prognostic value of a parameter was investigated by calculating the two-sided log-rank test 12, 13 for the survival curves of the different categories of the parameter using Statistica '98 release 5.1.
14 Five-years EFS rates of two randomization arms were also evaluated by calculating the 95% confidence interval (CI) of their difference. The prognostic value of each parameter over the combined cohort of three risk groups was analyzed with the stratified log-rank test, with stratification according to treatment.
To investigate the combined prognostic value of the parameters found to be significant in the univariate analysis, a Cox regression was applied with stratification according to treatment.
Results
Patients
The DCLSG co-operation covers nearly all patients diagnosed in The Netherlands. From October 1991 to December 1996, 515 consecutive children with de novo ALL were diagnosed in The Netherlands; 509 of them were eligible for protocol ALL-8. Four hundred and sixty-seven (92%) were registered on the ALL-8 study. Forty-two (8%) did not enter the study, because of institutional choice (24 patients), missing data (14 patients), patient's refusal (one patient), or discrepancy in laboratory test (three patients). Of the 467 patients on study, 422 Leukemia (90%) were registered by pediatricians in university hospitals, 45 (10%) by pediatricians in general hospitals. Patient and disease characteristics of the 467 eligible patients are summarized in Table 2 . No significant differences in patients' characteristics were observed between the 467 protocol and 42 non-protocol patients (data not shown). Of the 467 protocol patients, 170 (36.4%) were stratified into the SRG, 241 (51.6%) into the MRG and 56 (12%) into the HRG. Patients were stratified into the HRG because of an acute undifferentiated leukemia (AUL) (CD10 and TdT negative) (three patients), t(9;22) (eight patients), t(4;11) (five patients), poor steroid response (30 patients comprising 6.4% of all patients, 53.6% of HRG patients), and no complete remission on day 33 (10 patients). Patient characteristics according to risk group are summarized in Table 2 .
Treatment results
Treatment results are based on intention to treat. Induction treatment according to protocol I could be evaluated in 462 out of eligible 467 patients: two MRG patients died of cerebral hemorrhage before treatment could be started.
Induction treatment could not be evaluated in three patients because of missing data, or investigator's choice. Two patients died early during induction treatment: one MRG patient with Down syndrome died of sudden cardiac arrest; one HRG patient died of cerebral hemorrhage; two other patients failed to respond to induction therapy and died. Four hundred and fifty-eight (99%) patients achieved a complete remission according to protocol (Table 3) .
After complete remission protocol deviations occurred in 59 patients, for one patient essential data are missing and one patient was lost to follow-up.
One hundred and six patients relapsed, 56 during, 50 after therapy; 12 of these patients relapsed after major treatment deviations. The site of relapse is shown in Table 3 . The majority (Ͼ80%) of the relapses occurred in the bone marrow. In contrast to the previous study ALL-7, in which no CNS relapses occurred in SRG patients receiving protocol II, in this study three SRG patients suffered from isolated CNS relapse, 5, 8 and 20 months after first CR, respectively. These patients were heterogeneous for age, sex, initial platelet counts, immunophenotype and karyotype. CNS directed treatment was applied according to protocol. None of these patients had received HD-L-Asp during maintenance treatment. None of the nine MRG and two HRG patients with isolated CNS (MSD-BMT) ; seven died. Six children were transplanted with bone marrow from a matched unrelated donor; two of them died. Two patients underwent haploidentical BMT (father donor); one patient died.
Seven out of 458 patients who achieved CR, died in first CR, four of them after protocol deviation. The causes of death were: massive necrotizing aspergillosis, sudden death by myocarditis (diagnosed at autopsy), encephalopathy, fatal hepatitis post-BMT (adenovirus), graft rejection after haplo-identical peripheral blood stem cell transplantation, cerebral hemorrhage in thrombopenic phase after protocol I, septicemia of unknown origin.
Three hundred and forty-three patients are alive and in first complete remission at last follow-up (median follow-up of patients event-free alive: 60 months; range 35-98 months).
The estimated 5-year survival is 82% (s.e. 2%) for the total group of 515 patients, 83% (s.e. 2%), for the 467 protocol patients ( Figure 1 ) and 83% (s.e. 6%) for the 42 non-protocol patients; estimates for 5-year event-free survival are 72% (s.e. 2%), 73% (s.e. 2%) (Figure 1 ) and 71% (s.e. 8%) respectively. There is no significant difference in the event-free survival of protocol patients and non-protocol patients (logrank P = 0.82).
The 5-year event-free survival for SRG patients is 85% (s.e. 3%), for MRG patients 73% (s.e. 3%) (logrank P = 0.002), for HRG patients 39% (s.e. 7%) (logrank P Ͻ 0.001 vs SRG and vs MRG) (Figure 2 ).
The 5-year event-free survival rates for patients with precursor-B ALL and T-ALL according to the National Cancer Institute Risk classification are given in Table 4 .
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Figure 1
Survival and event-free survival (EFS) of 467 newly diagnosed ALL-patients treated according to DCSLG Protocol ALL-8: (. . . . ) survival; (--) event-free survival.
Figure 2
Event-free survival (EFS) according to risk group. Stratification after treatment with DCLSG Protocol ALL-8: SRG, standard risk group; MRG, medium risk group; HRG, high risk group.
The estimated cumulative risk for isolated CNS relapse at 5 years is 4% (s.e. 1%) for the total group of 467 patients (14 CNS relapses) and 3% (s.e.1%) for patients without initial CNS involvement (n = 455). In patients without initial CNS involvement, no differences in isolated CNS relapse were observed between T-ALL and precursor B-ALL patients or between T-ALL patients with high and low WBC at diagnosis ( Table 5 ). The cumulative risk of any CNS relapse at 5 years is 5% (s.e. 1%) for the 467 patients (18 CNS relapses). There was a marginal significance for high WBC values (у100 × 10 9 /l) (logrank P = 0.05), but no relationship with immunophenotype.
For the 12 patients with initial CNS involvement, the EFS at 5 years is 58% (s.e. 14%): one patient died before treatment was started; for one patient who died in CR 22 months after diagnosis the cause of death is unknown; three patients relapsed (two in the bone marrow, one in the CNS); seven patients have been in CCR for 45-93 months.
Randomized study on HD-L-Asp during maintenance treatment in SRG patients (IDH protocol)
One hundred and sixty-five patients were eligible for randomization; for 80 (48%) patients randomization was refused; 85 (52%) patients were randomized; 42 into SRG1 (no HD-L-Asp), 43 into SRG2 (with HD-L-Asp). The reasons for this high percentage of non-randomization were: refusal by patient and/or parents (n = 47), clinical decision (n = 20) and other (n = 13). The majority of the non-randomized patients (79 out of 80) had chosen maintenance treatment without HD-L-Asp, only one patient chose addition of HD-L-Asp to maintenance treatment. The randomized patients and the non-randomized patients had rather similar EFS curves (logrank P = 0.91) at 5 years 85% (s.e. 4%) and 86% (s.e. 4%), respectively. The nonrandomized group had slightly more females (P = 0.04) and slightly different hemoglobin levels (P = 0.005) and platelet counts (P = 0.021); there was no significant difference for age, WBC, DNA index, immunophenotype and FAB.
Between patients of both randomized groups there were no significant differences in age, sex, Hb, WBC, platelet counts, karyotype and DNA index at diagnosis. (24) 67 (5) 42 (75) 67 (6) Total 382 (100) 76 (2) 56 (100) 71 (6) The estimates for an event-free survival at 5 years were not significantly different for SRG1 and SRG2 patients: 82% (s.e. 6%) and 88% (s.e. 5%), respectively (logrank P = 0.58). However, we have to realize that the uncertainty in these results is still great in view of the number of patients. The improvement with HD-L-ASP is estimated to be 88%−82% = 6%, with a standard error of {6 2 + 5 2 } . = 7.8%. The 95% CI for this difference runs from −9.6% to +21.6%.
Randomized study on HD-6MP during protocol M in MRG patients
Two hundred and thirty-five patients were eligible for randomization: for 57 (24%) randomization was refused (30 patient's refusal, seven clinical decisions and seven other); 178 patients were randomized: 91 into MRG1 (conv. 6-MP), 87 into MRG2 (HD-6MP). The majority of the non-randomized patients (54 out of 57: 95%) had chosen protocol M with conv. 6MP; only three patients preferred treatment with HD-6MP.
For randomized (n = 178) and non-randomized (n = 57) patients the 5-year EFS rates were quite similar: 74% (s.e. 3%) and 72%, (s.e. 6%), respectively (logrank P = 0.95); there were no differences in sex, age, Hb, leukocytes, thrombocytes, DNA index and FAB.
Between patients of both randomized groups there were no significant differences in age, sex, risk factor, Hb, WBC, platelet counts, DNA index, karyotype, immunophenotype, incidence of mediastinal mass or extramedullary involvement.
The estimates for an event-free survival at 5 years were not significantly different for MRG1 and MRG2 patients: 75% (s.e. 5%) and 72% (s.e. 5%) respectively (logrank P = 0.48). The difference is estimated to be 75%-72% = 3%. Taking into Leukemia account the 95% CI of this difference, it will be de facto between −11.2% and +17.2%.
Prognostic factor analysis
The prognosis for infants (Ͻ1 year of age at diagnosis) proved to be extremely poor ( Figure 3 ): none of them survived eventfree beyond 3 years; the median EFS was 10 months.
Since age Ͻ1 year was of such a significant influence on the outcome, infants were excluded from the prognostic factor analysis. The results of the univariate analysis of the remaining 454 patients and stratified by treatment (SRG, MRG and HRG) are shown in Table 6 . The usual characteristics were analyzed: WBC was analyzed in two categories; the prednisone response at day 8, categorized as Ͻ10 vs у10 blasts/mm 3 in the peripheral blood, proved to be prognostic. Sex and ploidy were the only prognostic factors for SRG patients. For MRG patients sex, WBC at diagnosis, prednisone response at day 8 and the percentage of blasts in the bone marrow at day 15 were significant prognostic factors. For HRG patients no significant prognostic factors could be determined.
A multivariate Cox regression analysis included variables significant in the univariate analysis presented in Table 6 : sex, WBC (Ͻ50 vs у50 × 10 9 /l), prednisone response at day 8 (Ͻ10 vs у10 blasts/mm 3 ) and the percentage of blasts in the bone marrow at day 15 (M1: Ͻ5%, M2: 5-25% and M3: у25%). Three factors showed independent prognostic information: boys had a worse prognosis compared to girls; an M3 marrow at day 15 or a WBC у50 × 10 9 /l were unfavorable
Figure 3
Event-free survival (EFS) according to age. prognostic factors. Prednisone response at day 8 lost its significance ( Table 7) .
Comparison of treatment results (Table 8)
The overall results of protocol DCLSG ALL-8 tend to be better than those of the previous protocol DCLSG ALL-7 (2) (logrank P = 0.043). This is mainly due to better results in SRG and MRG patients. In contrast, the treatment results in ALL-8-HRG patients tended to be inferior to the results in ALL-7-EG patients (logrank P = 0.19).
The results of DCLSG ALL-8 are almost identical to those of the Italian protocol AIEOP non-B-ALL-91, 16 which is also based on protocol ALL-BFM-90. The most favorable results were obtained in Germany with the original protocol BFM-ALL-90.
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Discussion
The overall treatment results of protocol DCLSG ALL8, the second BFM-oriented protocol applied in The Netherlands, tend to be better than those of the previous study ALL7. 2 This is partly due to the application of protocol II for SRG patients and prolongation of the total treatment duration up to 24 months, but may also reflect a learning effect. 
Leukemia
The 5-year EFS for ALL8 patients is within the range of contemporary studies, recently published. 17 The results of the DCLSG ALL-8 study confirm the conclusion of the previous DCLSG ALL-7 study, the AIEOP-ALL91 study and the INS 89 trial, that BFM-oriented treatment without cranial irradiation leads to comparable overall treatment results as the original BFM treatment with cranial irradiation. 2, 17, 18 The CCG-105 study, involving intermediate risk ALL patients (including 44% of all newly diagnosed patients) has already demonstrated no significant differences in CNS relapse rate, EFS or survival between patients who in BFMoriented treatment received intrathecal methotrexate only as CNS prophylaxis as compared with cranial irradiation. 19 The DCLSG ALL8 study shows that the majority (94%) of newly diagnosed patients can be spared cranial irradiation without jeopardizing the favorable BFM treatment results.
The results of two recently published studies also support the idea that cranial irradiation can be omitted altogether. In the EORTC study 58881, which like the DCLSG ALL-8 protocol was also based on the ALL-BFM 90 protocol, the 5-year EFS was 70.9%, with a cumulative incidence rate of isolated CNS relapse of 4%. 20 In the MD Anderson Cancer Center pilot studies 8609/8604 these percentages were 60.7 and 3%, respectively. 21 It has been suggested that cranial radiotherapy is still necessary for T-ALL patients with initial WBC у100 × 10 9 /l. 22 In the DCLSG ALL-8 study no significant differences were found in the 5 year CNS relapse rates of patients with WBC Ͻ100 × 10 9 /l and у100 × 10 9 /l, regardless of the prednisone response. Since the number of T-ALL patients is relatively small, the results of T-ALL patients treated according to DCLSG protocol ALL-7 were added to those of the protocol ALL-8, to a total of 83 patients. Again, no significant difference could be shown (P = 0.86).
The overall ALL-BFM 90 results are somewhat better than the ALL-8 results and this is mainly due to better results in MRG patients in the BFM group, in particular in standard risk B-lineage patients. 3 Whether this can be attributed to the addition of 12 Gy of radiotherapy, remains unclear.
Prolonged exposure to asparaginase has been of benefit in some treatment strategies. 23, 24 However, in our SRG patients the addition of 20 weekly doses of HD-L-ASP during maintenance treatment did not improve the outcome, but the number of randomized patients is small. Different strains of asparaginase have been shown to have different half-lives of activity. 25 The use of Erwinia asparaginase instead of Escherichia coli or polyethyleneglycosylated (PEG) asparaginase in our study and in the recently published Italian AIEOP-ALL 91 Study 5 may partially explain why in these studies no benefit was observed of high-dose asparaginase intensification.
Also, no differences in treatment results were observed between MRG patients receiving conventional 6MP or HD-6MP. Although the numbers of patients are small, these results are in line with the results of the EORTC 58881 study, in which monthly i.v. 6-MP (1 g/m 2 ) during maintenance even had a deleterious effect and increased the relapse rate. 20 This may indicate that a continuous moderate level of cytotoxic thioguanine nucleotides is more effective than short lasting peak levels. The pharmacodynamic and pharmacokinetic results of this study will be published separately.
One of the objectives of the ALL-8 protocol was to further reduce treatment for SRG patients. In contrast to previous BFM and DCLSG studies, in which the elimination of protocol II (delayed intensification) had a dramatic negative effect on EFS for SRG patients, 2,26 the elimination of the second part of protocol I did not increase the risk of relapse for SRG patients: the estimated 5-year EFS for SRG patients treated according to protocol ALL-8 was 85% (s.e. 3%), compared to 86.6% (s.e. 1.4%) for SRG patients treated according to protocol ALL-BFM 90, who had received the complete protocol I. 3 The treatment results in HRG patients (5-year EFS 39% s.e 7%) are as poor as in the ALL-BFM 90 study (6-year EFS 34% s.e. 3%), 3 indicating, however, that the omission of cranial irradition in the Dutch patients has not further deteriorated the outcome; therefore, other negative factors must have played a role, such as the total amount of chemotherapy applied and the frequent therapy-free intervals caused by this very intensive, rotational treatment. 3 Male sex proved to be an independent risk factor in patients over 1 year of age. A sex difference has been reported previously. [27] [28] [29] A lower incidence of a favorable DNA index has been suggested as part of an explanation for the inferior prognosis for boys, but DNA index was not of prognostic value in this study. Comparison of pharmacological end points of methotrexate, teniposide, cytosine arabinoside and thiopurine methyltransferase activity showed no difference for boys and girls, 29 nor did in vitro sensitivity testing using the MTT test for 13 drugs, including steroids, vincristine, L-asparaginase, anthracyclines and 6-mercaptopurine. 30 Based on the observations that myelosuppression during maintenance treatment 27 and a high cumulative dose of 6-mercaptopurine correlates with a better prognosis, 31 it has been suggested that extended maintenance treatment or early intensification might improve the cure rate for boys.
In patients over 1 year of age both the tumor load, determined by WBC and the early response to therapy, assessed in the bone marrow at day 15, were also independent prognostic factors. The predictive value of these factors has been widely reported, both in BFM studies 26, 32 and in studies by others. 33, 34 Risk-adapted therapy, based on these factors, has improved the overall treatment results in childhood ALL. Treatment stratification also based on the assessment of minimal residual disease and the dynamics of blast cell clearance by PCR techniques 35 or based on the in vitro chemosensitivity of leukemic cells assessed by the MTT test 36 may further improve the prognosis for children with ALL. These new techniques are being evaluated in the current protocol DCLSG ALL9. In this protocol the prognostic significance of doctors' and patients' compliance during treatment is also investigated. 37 For ALL non-high risk patients (defined as WBC Ͻ50 × 10 9 /l, no CNS involvement and/or mediastinal mass), the results of the very intensive chemotherapy of protocol ALL8, including anthracyclines and alkylating agents, are not superior to those of the previous DCLSG protocol ALL6 for ALL non-high risk patients, which has resulted in a 10-year EFS of 82% (s.e. 3%). 38, 39 Despite the large dose of dexamethasone applied in protocol ALL6, bone mineral density, body composition and heights were normal in a representative number of long-term survivors. 40 In a retrospective study among 540 children, treated according to the DCLSG Protocols ALL6, ALL7 or 8 (166, 172 and 202 patients, respectively) avascular osteonecrosis (AVN) was reported in none of the children treated according to ALL6, in five and four children treated according to ALL7 and ALL8, respectively, suggesting that the incidence of AVN may not be dependent upon dexamethasone alone. 41 Less intensive chemotherapy for a large proportion of children with ALL reduces both toxicity and costs, the latter being especially important for treatment for children in less privileged countries.
